Thalidomide 4'-oxyacetamide-alkyl-C2-amine hydrochloride is primarily investigated for its potential therapeutic applications in targeted drug delivery systems. Its modified structure allows for enhanced binding affinity to specific biological targets, making it a promising candidate for treating certain cancers and autoimmune diseases. The compound’s ability to modulate immune responses and inhibit angiogenesis is particularly valuable in oncology, where it can be used to suppress tumor growth and metastasis. Additionally, its tailored alkyl chain improves solubility and bioavailability, facilitating more efficient drug administration. Research is ongoing to explore its efficacy in combination therapies and as a standalone treatment for conditions like multiple myeloma and inflammatory disorders.